Code Biotherapeutics is developing a multivalent synthetic DNA delivery platform, 3DNA®, to enhance the precision and bioavailability of non-viral gene therapies for life-threatening diseases. The company focuses on overcoming challenges such as dose-related toxicity and off-target effects, with a primary research emphasis on Duchenne Muscular Dystrophy.
Funding
$85M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Current gene therapy delivery methods face challenges such as dose-related toxicity, off-target effects, immunogenicity, limitations on gene size and delivery, bioavailability issues, inability to re-dose, and complex vector manufacturing processes. These limitations hinder the effective treatment of life-threatening diseases.
Solution
Code Biotherapeutics is developing a multivalent synthetic DNA delivery platform, 3DNA®, designed to enhance the precision and bioavailability of non-viral genetic medicines. The 3DNA® platform is engineered to overcome limitations associated with existing delivery methods by improving cell-specific targeting, bioavailability, and modularity for delivering multiple modalities. This approach aims to minimize off-target effects and improve the overall safety and efficacy of genetic medicines. The company is advancing an internal pipeline focused on various diseases, with its most advanced research targeting Duchenne Muscular Dystrophy (DMD).
Target Audience
The primary target audience includes patients suffering from life-threatening genetic diseases, particularly Duchenne Muscular Dystrophy (DMD), and pharmaceutical companies seeking advanced gene therapy delivery solutions.
Features
- Multivalent synthetic DNA delivery platform (3DNA®) for enhanced precision and bioavailability.
- Engineered to overcome dose-related toxicity, off-target effects, and immunogenicity.
- Improved cell-specific targeting for precise delivery of genetic medicines.
- Modularity to deliver multiple modalities.
- Research programs underway targeting the lungs, pancreas, and liver.